Equities

StageZero Life Sciences Ltd

StageZero Life Sciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.04
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-33.33%
  • Beta0.0668
Data delayed at least 15 minutes, as of Sep 19 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

  • Revenue in CAD (TTM)--
  • Net income in CAD--
  • Incorporated1997
  • Employees40.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Appili Therapeutics Inc827.41k-3.82m3.64m7.00------4.40-0.0315-0.03150.0068-0.10210.3758--0.6463118,201.40-173.36-128.44---251.87-----461.35-2,103.81---3.30----147.59--59.09--17.59--
Marvel Biosciences Corp0.00-2.10m4.48m-----------0.0529-0.05290.00-0.06930.00-------268.48-----------------14.33--------10.29------
StageZero Life Sciences Ltd-100.00bn-100.00bn4.90m40.00---------------0.1119-----------135.76-------2.74---246.920.0176-------25.1255.93-52.53------
Innovotech Inc1.23m-364.50k5.27m16.00--7.22--4.29-0.0094-0.00940.03150.01871.105.815.84---32.592.90-37.993.5668.6371.56-29.672.192.17--0.1115--5.057.42-15.43--35.69--
Principal Technologies Inc618.64k-1.90m5.53m----9.11--8.94-0.0766-0.07660.02460.01650.5664--2.92---170.72---445.11--21.57---301.45-----31.950.0959--25.43--23.53------
Quest PharmaTech Inc0.0012.69m5.92m0.000.46650.26570.4665--0.0750.0750.000.13180.00------50.737.6253.018.45------------0.0430.00----95.35------
XORTX Therapeutics Inc0.00-2.01m7.17m3.00--1.96-----0.6792-0.67920.001.260.00-------23.54-35.42-29.36-40.37------------0.03------72.04--7.91--
Data as of Sep 19 2024. Currency figures normalised to StageZero Life Sciences Ltd's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.